Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

Registrati

Quotazioni in diretta

VRTX Vertex Pharmaceuticals Inc

463,5799

25,18 (5,74%)

01 Feb 2025 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/15/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/08/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for David Altshuler

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Vertex Pharmaceuticals (NASDAQ:VRTX)
Storico
Da Gen 2025 a Feb 2025

Clicca qui per i Grafici di Vertex Pharmaceuticals

Grafico Azioni Vertex Pharmaceuticals (NASDAQ:VRTX)
Storico
Da Feb 2024 a Feb 2025

Clicca qui per i Grafici di Vertex Pharmaceuticals

Notizie Vertex Pharmaceuticals Inc - VRTX

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Venerdì 31 Gennaio 2025 (23 ore fa) • Business Wire

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Venerdì 31 Gennaio 2025 (1 giorno fa) • Business Wire

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
Lunedì 27 Gennaio 2025 (5 giorni fa) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 17 Gennaio 2025 (2 settimane fa) • Edgar (US Regulatory)

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Domenica 12 Gennaio 2025 (3 settimane fa) • Business Wire

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
Venerdì 10 Gennaio 2025 (3 settimane fa) • Business Wire

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Martedì 7 Gennaio 2025 (4 settimane fa) • PR Newswire (US)

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Lunedì 23 Dicembre 2024 (1 mese fa) • Business Wire

Form 8-K - Current report
Venerdì 20 Dicembre 2024 (1 mese fa) • Edgar (US Regulatory)

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Venerdì 20 Dicembre 2024 (1 mese fa) • Business Wire

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Venerdì 20 Dicembre 2024 (1 mese fa) • Business Wire

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
Giovedì 19 Dicembre 2024 (1 mese fa) • Business Wire

Più Vertex Pharmaceuticals Inc Articoli Notizie

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea